Advertisement
Dr. Hung will provide an overview of Medivation and its clinicaldevelopment programs for Dimebon(TM) for Alzheimer's and Huntington's diseasesand MDV3100 for prostate cancer.
Advertisement
The Company reported results from its Phase 2 efficacy study of Dimebon inAlzheimer's disease in June 2007, showing that Dimebon improved the clinicalcourse of patients by demonstrating meaningful improvement over placebo ineach of the five disease aspects most important to patients, caregivers andphysicians -- memory, thinking, activities of daily living, behavior andoverall function. Significant gains in these disease aspects were evident asearly as the twelfth week of treatment. After six months of treatment,patients were significantly better off than they were at the start of therapyon all key aspects of the disease. Dimebon's overall benefit compared toplacebo continued to increase over time and was greater at 12 months that atsix months.
A live audio webcast of the presentation will be available on the "Eventsand Presentations" page of the "Investor Relations" section of the Company'swebsite at www.medivation.com. A replay also will be available for 30 daysfollowing the live presentation.
About Medivation
Medivation, Inc. is a biopharmaceutical company that acquires promisingtechnologies in the late preclinical development phase and develops themquickly and cost-effectively. Medivation's current portfolio consists ofsmall molecule drugs in clinical development to treat three large, unmetmedical needs -- Alzheimer's disease, Huntington's disease and hormone-refractory prostate cancer. The Company intends to build and maintain aportfolio of four to six development programs at all times. For moreinformation, please go to www.medivation.com.
SOURCE Medivation, Inc.
